Opus Genetics (IRD) COO Joseph Schachle Receives 250,000-Share Award

What Happened

• Joseph K. Schachle, COO of Opus Genetics (IRD), received a grant of 250,000 restricted stock units (RSUs) on 2026-01-22. The filing reports an acquisition price of $0.00, so the grant is compensation rather than a market purchase.

Key Details

• Transaction date: 2026-01-22; Form 4 filed: 2026-01-26 (filed four days after the transaction).
• Amount: 250,000 RSUs; reported acquisition price: $0.00 (total reported value = $0).
• Vesting: RSUs vest in substantially equal quarterly installments over the next 16 quarters, subject to Mr. Schachle’s continued service (per footnote).
• Shares owned after the transaction: not specified in the provided excerpt.
• Filing timeliness: Form filed on Jan 26 for a Jan 22 grant. Section 16 filers typically must file Form 4 within two business days, so this appears later than the usual two-business-day window (the filing itself should be reviewed for any late-filing designation).

Context

• This was an award of RSUs (compensation), not an open-market purchase or sale. Such grants are common for executive compensation and do not by themselves indicate a buy/sell signal; value will be realized as units vest and convert to shares (subject to service and company policies).